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Sleep and the Fitness to Drive:
A Swiss Perspective
Stefan Lakämper and Kristina Keller
Abstract
Medical conditions and behavioral patterns affecting sleep are a largely
underestimated threat to traffic safety. Unsupervised or even illegal self-treatment
of sleep issues by, for example, anti-histamines, cannabis products, or stimulants,
questions safe driving and the fitness to drive as well as low compliance/adherence
to treatments (CPAP, medication, etc.) of medical conditions, such as OSAS, or
narcolepsy. In such cases, Swiss law calls for a medical assessment of the fitness to
drive by experts in traffic medicine. With increasing complexity, this medical
assessment is escalated in a four-tiered system of qualified experts, ranging from a
qualified practitioner to experts in traffic medicine, at, for example, an Institute for
Legal Medicine. The following overview provides insight in the Swiss framework of
traffic medicine assessments that – with all caveats and potential drawbacks – helps
mitigating the risk of sleep-related accidents. For this, we first introduce Swiss
traffic medicine and then argue for consistent terms and measurements to assess
sleepy driving. A concise summary of those sleep related conditions most relevant
in traffic medicine is followed by an overview over potential issues of
sleep-medication.
Keywords: sleep, fitness to drive, traffic medicine, OSAS, narcolepsy,
sleep medication
1. Introduction
The consequences of medical conditions and behavioral patterns negatively
affecting sleep pose a largely underestimated threat to traffic safety. According to a
recent survey of Swiss road safety authorities (ASTRA), about 2% of all car acci-
dents in Switzerland are documented to be caused unequivocally by the driver
falling asleep [1]. Similar numbers are reported from other countries. The U.S.
Institute for Insurance Information (III) lists “drowsy, asleep, fatigued, ill or
blacked out” operation in 2.4% of drivers/operators involved in fatal crashes [2] and
the U.S. National Highway Traffic Safety Administration (NHSTA) reports 1.9% of
fatalities in motor vehicle crashes to have involved drowsy driving [3].
However, the estimated number of undetected or unreported accidents and
fatalities might be much higher: various sources suspect that up to 30% of all
accidents can be related – in part or full – to either falling asleep or to sleepiness at
the wheel [4–6]. A study commissioned by the Australian Sleep Health foundation
[7] and summarized prevalence and prevention information by the U.S. Center for
Disease Control (CDC) [8] indicate that a surprisingly large fraction of the
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respective population suffers from undiagnosed sleep deprivation. In a representa-
tive poll, 1 in 25 U.S. adult drivers (ages 18 or older) report to have fallen asleep
while driving in the last 30 days [9]. The NHSTA estimates that drowsy driving was
responsible for 72,000 crashes, 44,000 injuries, and 800 deaths in 2013. These
numbers are likely underestimated, and up to 6,000 fatal crashes each year may be
caused by drowsy drivers in the U.S. alone [8, 10–12].
While the two preceding paragraphs illustrate the scope (of the threat/risk/chal-
lenge) with (impressive) figures, they also highlight a fundamental problem for
mitigation strategies and concepts, i.e. an apparently incomplete definition and
demarcation of terms used above, such as “drowsy, asleep, fatigued, ill, [… ] blacked
out” [2], unconscious, tired, sleep-deprived or sleepy. The large spectrum of terms in
use is in contrast to the need of a medical expert to communicated clearly and in a
specific manner, not only with peers, but also in court, in assessments for authorities
issuing driving licenses, and – last but not least – with his patients.
To briefly provide a few – possibly trivial, but illustrative – examples: it is
essential if an unconscious patient caused an accident because he fell asleep or due a
“black-out” (transient loss of consciousness, TLoC). Similarly, it is important
whether a driver reports a “permanent subjective feeling of tiredness”, or lacks any
pre-sensation of spontaneously falling asleep in irregular intervals. While the latter
might indicate narcolepsy, the first might possibly be very distracting from and
dangerous for driving (inattention), but it might be short of any measurable danger
to actually fall asleep. Chronic sleep-deprivation or sleep-fragmentation might lead
to clearly measurable daytime sleepiness (excessive daytime sleepiness, EDS), but
this might remain completely unnoticed to the driver. Over time, the driver’s might
have lost the ability to distinguish sleepiness from a (transient morning-) drowsi-
ness or a post-prandial fatigue might have eroded, irrespective of the causes.
In the best case, any of the above conditions or situations is known ahead of any
incident and family practitioners and experts in sleep- and traffic medicine collab-
orate for the best possible treatment and control to prevent any (daytime) sleepi-
ness, in particular while driving.
However, one or more of the above situations or conditions might remain
undetected, resulting, in the worst case, in an accident truly caused by the driver
actually falling asleep. Such accidents, briefly termed sleep accident (SA) in the
following text, usually exhibit certain characteristics. Drivers crash on a well-
known monotonous road stretch, close to the final destination (e.g. home or work).
Typically, there are no detectable traces of braking, of avoiding obstacles/vehicles
or of abrupt changes in direction. In addition, drivers are usually well oriented and
responsive in a clear and alert manner immediately following the accident [13].
However, indications are not always as clear and it is the second very mandate of
traffic medicine to identify and document the causes of such accidents post hoc.
As already seen before, reasons for (daytime) sleepiness can be numerous and
divers. Statistical figures hint at how one could structure a description of causes on a
first level: the predominant fraction of SAs of drivers under 40 happen in weekend
nights. In contrast, sleep accidents of drivers above 40 happen mostly on weekdays
in the (late) afternoon [4]. Thus, following a dichotomization in “the younger
partying” and “the older suffering from xx”, the reasons can be divided very
coarsely in predominantly behavioral or medical.
On a second level, the first might be further detailed in behavioral, social,
professional and environmental reasons, whereas the latter might stem from cen-
tral, neurological, somatic or psychiatric conditions or, finally, be substance- or
medication-induced (See Table 5 in Chapter 3).
On a third level, that is also important for an overall assessment in traffic
medicine, behavioral and social patterns overlaying fundamental causes might
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further aggravated the sleep conditions and associated risks in traffic. Especially in
affluent and highly developed countries, with dense traffic and high social stress,
sleep conditions are often counteracted by excessive use of commercially available
stimulants (caffeine) or over the counter (OTC) substances (melatonin,
doxylamine, diphenhydramine). Rather than addressing the problem, masking it by
(an often inappropriate) use of such remedies already hampers mitigation of the
risks. At the same time, several rounds of “next generation” sleep medication have
repeatedly shown to involve the danger of developing tolerances, rebound- or side-
effects, and even addiction. Especially latter is relevant in the context of self-
medication and off label use of prescribed medication (antidepressants) or even
drug abuse (cannabis, upper/downer, and opioids [14]), potentially causing
unpredictable drug interactions leading to sudden sleepiness or TLoCs (Table 1).
The preceding paragraphs already outline the overall structure of the chapter
and briefly sketch order and content of its sections: First, we introduce the unique
set-up of Swiss traffic medicine, some necessary legal terms and recent organiza-
tional developments. We then argue for consistent use of terms and measurements
used in the assessment of sleepiness. Following is a brief overview over those sleep
conditions most relevant in every-day traffic medicine, including respective treat-
ment options that are relevant to follow-up assessment. Lastly, we illustrate dangers
of uninformed or inappropriate use of hypnotics and antidepressants due to drug
interactions, highlighting the particular power of hair-analysis.
The chapter mostly collects regulations and existing literature. However, it is
supplemented with two case reports and a short report on case numbers from the
database of the division of traffic medicine at the Institute of Forensic Medicine at
the University of Zurich.
2. Traffic medicine in Switzerland
To mitigate risks in traffic in general, Swiss license holders have to fulfill medical
minimum requirements (MMR) by law (Strassenverkehrsgesetz, SVG Art 14 & 15
d, and Verkehrszulassungsverordnung, VZV, Art 7 [15, 16]). Swiss legislation
already defined these “medical minimum requirements “(MMR) in 1932 in the form
Signs of sleep accident Signs of TLoC-accidents
Monotonous, well known route —
Close to destination —
No trace of breaking No trace of breaking
Immediately oriented driver Continued disorientation
Diffuse knowledge about falling asleep Despair about unclarity of causes
Rather trying to obscure clarifications Strong interest in clarifying causes
Drivers aged <40: rather weekend nights Independent of age
Drivers aged >40: rather afternoons Independent of age
Seen by other drivers Seen by other drivers
Slow reduction in speed Abrupt changes in direction
Slowly loosing track
Table 1.
Comparison of characteristic signs of sleep accidents as compared to accidents caused by a transient loss of
consciousness (TLoC).
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of ordinances [17]. These MMRs have been continuously modernized and adapted.
In addition, they are framed by detailed subject-specific guidelines.
It is thus surprising that – despite known fatalities due to sleep accidents, the
MMRs did, in fact, lack any explicit requirements with respect to sleep until 2016.
Only then, a revision of the VZV in the context of a large-scale legislative effort to
modernize and improve traffic (Via Sicura) specified in the MMR that there must
not be any diseases or conditions leading to “elevated” daytime sleepiness. How-
ever, who does determine whether such a condition is or was present, and how? Are
other contributing factors evaluated?
In general, the medical minimum requirements are controlled by experts trained
in traffic medicine, who are organized and trained in a four-tiered federation-wide
system, ranging from a trained physician (level 1) to full time experts (level 4, see
Figure 1) since 2016.
Within this system, the medical assessment is escalated depending on the cate-
gory of driving license applied for or increasing complexity, allowing for second
opinions in doubt up to a level-4 expert, who are mostly associated with institutes
for forensic/legal medicine. Among others, the law requires mandatory biannual
checkups of elder drivers above age 75 for all categories and mandatory control
exams for higher categories, such as professional taxi-, bus- or truck-drivers, after
3–5 years.
In the context of a sleep accident, the driver is in any case confronted with the
question whether falling asleep – and thus the accident – happened in negligence; in
other words, did the driver’s behavior or wrongdoing lead to falling asleep or can it
be attributed to a known or unknown medical condition. Apart from clarifying the
legal issue of liability, this has direct consequences on the driver’s license, as there
are - at least – justified doubts whether the driver can fulfill the MMRs. In Swiss
legal terms, it needs to be clarified whether the drivers momentary ability to drive
(ATD, German: Fahrfähigkeit) or the drivers general fitness to drive (FTD, Ger-
man: Fahreignung) was/or is given.
The legal term ability to drive (ATD,) refers to the driver’s momentary and
incidental physical and mental capabilities to safely conduct a vehicle. The ability to
drive safely can be impaired by, for example, alcohol, improperly used medication
and/or drugs. In addition, Swiss Federal Court rulings elaborate that in order for a
driver to be legally “able to drive”, both a basic capability and a mental and behav-
ioral reserve capacity is required. This reflects the need to be able react adequately
Figure 1.
Swiss four-tiered system of experts trained in traffic medicine.
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to unexpected incidences in traffic and thus refers to the driver’s requirement to
guarantee this capacity before while driving, i.e. behavioral aspects, habits or
character.
In contrast, the legal term “fitness to drive” (FTD) refers to the general physical
and mental prerequisites to safely conduct a vehicle, unrelated to a specific incident
or moment, relating obviously to chronic medical conditions limiting driving,
which is in conflict with the MMRs. An assessment of the FTD or ATD at the level 3
or 4 generally encompasses a cursory medical examination (traffic medical exam,
TME), anamnesis the patient’s general medical status, history and recent incidents/
events. Simple cognitive performance tests (mini mental status tests, clock test, trail
making tests) reflect the need to take into account the general performance capa-
bilities (German: Leistungsfähigkeit), assuming that safe driving requires both a
basic physical and mental capacity (for undisturbed traffic, German:
Grundleistung) as well as a mental and physical reserve capacity, relevant in
unforeseen situations (German: Reserveleistung) [18].
While lower level assessments formally check general health, compliance, and
adherence of, for example, the elderly drivers as required in two-year intervals at
ages 75 and higher, higher-level assessments clearly deal with substantial doubts in
the FTD, including those doubts relating to signs of addictive behavior and drug
abuse. The final assessment provide the decision base for the authorities issuing the
driving license.
According to recently updated guidelines [19], not all drivers who have caused a
presumed sleep accident have to undergo a full TME and TMA in a top-tier institu-
tion (level 4): it is mandatory if there is information or hints pointing at either a
medical condition or medication as the cause for falling asleep. In this case, the
driving license is temporarily revoked until the authorities further decide based on
the TMA. This is also the case, if it is unclear to both the driver and/or the author-
ities, whether the accident was truly caused by falling asleep or a transient loss of
consciousness (TLoC, see Section 2.1) [20]. In case the driver can plausibly explain
the accident by falling asleep due to behavior (too little sleep, shift work, etc.), a
TMA is not required and subsequent sanctions by the authorities rely fully on the
concession of an impaired driving ability.
2.1 Transient loss of consciousness as “camouflage statement” in sleep
accidents
Because a first-time TLoC based on a so far unknown medical condition is
presumed to have positive effects on the driver’s liability assessment, a TLoC is
often stated to “camouflage” any form misbehavior [21]. This is understandable in
the context of patients that are, for example, very well aware of their own low
medical or behavioral compliance/adherence, with known preconditions or psy-
chogenic and gar-related cognitive deficits. Here, shame and the fear of conse-
quences need to be taken into account.
A transient loss of consciousness (TLoC) as cause of an accident is already highly
unlikely if during the anamnesis of the accident situation the above-mentioned
characteristics can be found. However, this needs to be delimitated clearly; TLoCs
can be caused by cerebral hypo-perfusion of cardiac, orthostatic or reflex origin,
such as syncope, functional and medication arrhythmia, hypotonia, vasovagal
reflexes hyper-responsive baroreceptor reflex in the carotid sinus or – without
cerebral hypo-perfusion – by neurological, pharmacological or endocrinology con-
ditions, such as epilepsy, narcolepsy, intoxication, hypoglycemia. In addition, a
TLoC needs to be delimitated from other conditions such as a psychogenic
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pseudo-syncope, catatonia or cataplexy. The latter is often associated with narco-
lepsy and – in accident reconstruction – easily confused with falling asleep.
3. Sleepy driving: terms and measurements
The following section intends to take up the point of “incomplete definition and
demarcation of terms used” as described in the introduction and tries to link a
clarification to the legally binding - albeit slightly unclear - term “elevated daytime
sleepiness” from the MMRs in Section 2, by arguing for ideally using consistent
terms and measurements.
With “elevated daytime sleepiness” being the central term in Swiss legislation,
this section, thus, clarifies our understanding of a.) Sleepiness (What are the signs
of Sleepiness? What is sleepy? What is daytime sleepiness?) and b.) how to appro-
priately measure it? What is “elevated”, “excessive” … or – for that matter –
“existing” (measurable) daytime sleepiness?
3.1 Sings of sleepiness
Fundamentally and independent of the time of day, measurement condition or
cause, the state of “sleepy” displays unequivocal sings of imminent falling asleep. If
the sleep needed is avoided - either willfully or by external force - these sings
increase in frequency: if one is “sleepy”, one yawns often and attack-like. Further-
more, it is increasingly difficult to keep the eyes open and these are often felt as
“dry” and heavy (“heavy eyelids”). Muscle-tone and attention decrease signifi-
cantly. Vision is reduced in focus and perception speed, often leading to blurred or
even doubling pictures. In consequence, it becomes difficult to integrate environ-
mental input correctly and to react to them in timely manner. At the same time,
continued monotonous activities become erratic and concentrated. Sleepy test sub-
jects also report on changed temperature sensation (rather towards chilly) and
slightly increased perspiration (Table 2).
All these signs are believed to be noticed by all drivers [22, 23] well before
influencing the driving performance significantly [24]. However, it remains unclear
if, for example, chronically sleepy individuals (such as shift workers, truck drivers,
etc.) are still able to correctly judge these signs and/or act accordingly. This might
be influenced by continued willful ignorance and, thus,
familiarization/desensibilisation.
As mentioned above, there exists a general uncertainty as to how discriminate
the state of “sleepiness” from terms that are used in a similar or even synonymous
way: these include tiredness, exhaustion and drowsiness (see below). Lastly, the
difficulty to actually “measure” and “communicate a measure” of sleepiness should
not be underestimated, even in the medical and diagnostic context. Therefore, the
following section aims at clarifying terms and measures used in Swiss traffic
medicine.
3.2 Measures of sleepiness and its relevance in traffic medicine
As clarified in the preceding section, sleepiness per se is a natural reaction: it is
the direct presage of the functional and unavoidable necessity to sleep, as dictated
by chronobiology in (more or less) regular intervals, normally in the evening
[23, 25, 26]. Therefore and irrespective of the cause, be it medical or behavioral, the
customary composite “day-time sleepiness” describes an unusual and, in traffic,
inacceptable condition.
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Independent of the time of day, “sleepiness” also describes an initially abstract
measure of the inclination or tendency to fall asleep [27]. Transferred in a concrete
and manageable measurement, this measure is operationally defined as the
recorded time from a test start until a test subject actually falls asleep (in minutes),
i.e. a latency. This parameter is also termed “sleep latency”, but requires the actual
test situation to be named (see below). Although seemingly intuitive, but slightly
incorrectly, this parameter is also circumscribed as “sleep propensity” (Figure 2).
Figure 2(a) displays a schematic course of performance change during the day
in % (after [23]). Based on this, Figure 2(b) illustrates the measurement of sleep
latencies and allows clarifying the difference between the terms sleep latency and
sleep propensity (sleep inclination). Solid lines in red or blue, respectively, illustrate
schematically the “course” (on an arbitrary, qualitative scale ranging from “awake”
to “asleep”) from the start of the test (t = 0) until the test subject has fallen asleep
(crossing the x-axis). L1-L3 indicate three different sleep latencies. It is apparent
that on red and blue solid lines each result in the same sleep latency, but starting
from a different (abstract and qualitative) activity level. The dashed red and blue
lines, four of which are denoted as N1-N4, indicate the slopes (inclinations)
resulting from start and end of the measurements. N1-N4 help to illustrate the
slightly misleading term sleep propensity/inclination: given the same latency L1, N1
shows a steep slope, N2 displays a flat slope, as it starts form a lower activity level.
N2 is similar to N3, which relates to a much longer latency L3. Vice versa, N4 is
much smaller as compared to N3 although it corresponds to the same Latency L3. As
the latency has been made accessible through operationalization, the activity level
remains fully elusive. Consequently, the terms sleep inclination/propensity should
be avoided in favor of the clearly defined sleep latency. The same applies to terms
such as sleep pressure for which an illustrative correlate is even harder to find.
Sleep latencies are usually measured in two ways, the MSLT and the MWT [28].
Most frequent in sleep medicine is the classical multiple sleep latency test (MSLT).
Signs of sleepiness
Yawning (repeated, in attacks)
Dry eyes
«heavy eye lids
Sharp vision requires effort
Reduced muscle tone
Reduced attention, effort for vigilance strongly increased
Changed temperature sensation
Sweating (forehead)
Consequences for perception and performance in general
Visual perception slowed down and blurred
Slowed and error prone integration of environmental influences
Monotonous actions/tasks increasingly erratic and unconcentrated
Effects on driving performance
Track and speed cannot be held constant
Unexpected reduction of speed, inexplicable for others
Abrupt corrections of speed and direction when waking up
Table 2.
Unequivocal signs of being sleepy at the wheel.
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In four or five repetitions at intervals of 2 h, it is observed, if - and how fast - a test
subject is falling asleep within 20 min. Individuals are subjected to a typical sleep
setting: she/he is lying in a bed in a fully darkened room with closed eyes and with
the purpose to fall asleep. Once the EEG registers a > 15 s stretch of one or more of
the three typical sleep states, the measurement stops and the individual is woken
up. Final MSLT sleep latency is the average of the 4–5 measurements. The MSLT
thus measures how fast a test subject can manage to fall asleep during the day.
The multiple wakefulness test (MWT) measures also a sleep latency, but
approaches sleepiness from the opposite perspective, i.e. the wish to stay awake.
Individuals are subjected to a soporific, but not ideal situation: she/he is sitting in a
comfortable chair in a partially darkened (dim) room with open eyes and with the
clear purpose not to fall asleep, i.e. to stay awake. Again, the above-mentioned 15 s-
rule for the EEG applies to determine after how long an individual has fallen asleep
within either 20 min. or - more usual - 40 min. Again, this latency is measured in
four or five repetitions with intervals of 2 h. Final MWT sleep latency is the average
of the 4–5 measurements. The MWT thus measures, how many minutes a person
can (actively) avoid falling asleep during the day. The MWT includes active ele-
ments and incorporates the ability of the test subject to counteract falling asleep.
Consequently, the MWT is considered more comparable to assessing a driving
situation than the MSLT [28, 29].
However, clinicians might use definitions of EDS and criteria of it in MWT/
MSLT differing from or overlapping with those in traffic medicine [28]. The new
ICSD-3 [30, 31] defines EDS as “daily episodes of an irrepressible need to sleep or
daytime lapses into sleep”. For disorders, such as narcolepsy and idiopathic
hypersomnia (IH), which require demonstration of objective sleepiness by the
multiple sleep latency test (MSLT), a mean sleep latency of 8 min on the MSLT is
required. This criterion is unchanged from the ICSD-2 and represents the best
compromise between sensitivity and specificity [32]. Here, the MWT is not specif-
ically mentioned as diagnostic tool, while its relevance in the clinic has been proven
useful for the evaluation of treatment success with respect to everyday life situa-
tions [28].
Swiss guidelines for traffic medical assessments allow for a modification of the
MWT, in slight favor of the drivers, the FTD-MWT: here is allowed to consume
usual amounts of beverages containing caffeine during breaks and to take one mid-
day nap of 20 min. Both is not allowed in the diagnostic classical MSLT and MWT.
In practice, the number of modified FDT-MWTs is, however, very low.
Figure 2.
(a) Schematic course of performance change during the day in % (after [23]). (b) Three exemplary courses of
activity from awake to asleep form two different starting levels (red and blue) including measured sleep
latencies (L1–L3, black arrows)). N1–4 (red and blue dashed lines) illustrate slopes (inclinations) to argue
against the terms sleep inclination or sleep propensity (see main text).
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In order to discriminated daytime sleepiness as measured predominantly by
MWTs from an increased demand of sleep due to neurological conditions, such as a
hypersomnia or a narcolepsy [28], the MWT is usually accompanied by poly-
somnography (PSG, classic, ad libitum) which should ideally follow directly after a
14-day period of actigraphy, including protocolling the sleep behavior [29].
Such “objective” measures of sleepiness as measured in MWT or MSLT should
be clearly distinguished from phenomenological experienced and questionnaire-
based, i.e. “subjective” sleepiness. Some questionnaires and methods (KSS, as well
as VAS-batteries), determined a “momentary and felt” sleepiness, whereas, for
example, the ESS determines the subjective estimate of sleepiness over a period of
time (usually 14 days) post hoc and in relation to representative situations and,
therefore, registers - at best - an average subjective feeling. Although often in use,
the ESS is strongly criticized for is high level of subjectivity [27]. Also, the ESS
offers low prognostic reliability, as the subjective estimate of sleepiness might
manifest differently in different, soporific situations, such as monotonous night
drives or similar [33].
3.3 Day-time sleepiness: qualifiers and guidelines
It is the very nature of the so-far mentioned tests that, in principle, they can
measure both the natural sleepiness induced by medical conditions and behavioral
patterns, both in the course of the day and at night. In realiter, these tests are almost
exclusively performed and related to the common daytime period, in order to
evaluate deviation from the norm.
Intermittent or chronic sleepiness during the day as measured by way of above-
mentioned objective methods is termed “daytime sleepiness”. However, in different
contexts the term is often complemented with varying qualifying adjectives: to state
two, the medical field generally prefers the term “excessive daytime sleepiness”
(EDS) [34] mostly in connection with insomnias and other conditions. As intro-
duced in Section 2, Swiss law prohibits driving with medical conditions leading to
any “elevated” (German: erhöhte) daytime sleepiness. Other qualifiers “signifi-
cantly increased”, “relevant”, “excessive” and “severe” daytime sleepiness, leaving
the reader often without respective information how to understand and value the
qualifier. German regulations have taken up this issue by clarifying that “any
measurable” daytime sleepiness is relevant to the assessment of the fitness to drive.
In this meaning, but for reasons of general understanding, we here continue using
the general term EDS.
Contrary to sleepiness (both in general and EDS), the concepts of “tiredness”,
“exhaustion” or even “fatigue”, often originating from a very broad spectrum of
psychogenic and chronic syndromes, are not very well accessible to latency mea-
surements. Apparently, latency measures – especially MSLT-measurements – pro-
duce even paradox information: while physical activity improves (i.e. reduces)
daytime sleepiness, the very broad and rather unspecific “tiredness” in the above
mentioned syndromes is aggravated by physical activity, but cannot me measured
in MSLT and MWT as these monotonous and soporific test situations do not repre-
sent a stimulus for sleep [35].
In consequence, the assessment of the fitness to drive in the case of a chronic
medical condition relating to sleep critically hinges on evaluating daytime sleepiness
(EDS) by way of MWT sleep-latency measurements. This is particularly important
in order to assess treatment progress and/or treatment compliance.
Current guidelines provide orientation to assess the fitness to drive as based on
MWT sleep latencies (Table 3). Per definitionem the MWT captures daytime sleep-
iness (EDS) at values <40 min. Empirical and normative data display that 97.5% of
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healthy test subjects can stay awake for more than 8 min and 59% for 40 min or
more [33, 36]. Current guidelines suggest a limiting MWT sleep latency of ≥34 min
as the limit to a relevant “excessive daytime sleepiness” (EDS), corresponding well
with the average sleep latency of 36.5 min [28]. However, the guidelines allow
leeway in as far as single sleep fragments and micro-sleep episodes might be
allowed, although their existence strongly recommends repeating the MWT after a
reduced control interval and/or improved therapy.
4. Relevant conditions in traffic medicine
As has become clear in Section 2 of this chapter, traffic medicine is – in some
way - a statutory service institution. Assessments are by order of (and paid for by)
the driver but serve the issuing authorities in deciding if or under which conditions
a driving license can be (re)-granted. The assessment covers all medical fields (see
MMR). While unclear conditions or problems might prompt further inquiries to
associated specialists, Traffic medicine is far from being a diagnostic or a treatment
institution, but rather a “medical detective’s office”.
This position encompasses, that a broad knowledge, long-term experience and a
keen eye/ear for potential inconsistencies in the stories told by drivers form the
basis of – often very standard and uniform - daily assessments and control exams.
This includes also, that many of the more severe or chronic conditions are, in
fact, managed by the family physician and associated specialists. Higher-level
expert in traffic medicine might thus check and confirm a lower level assessment
of a managing doctor based on records and statements, but might not see the
patient directly. To give an example unrelated to this books topic, a well-
controlled diabetic is only rarely required to undergo a level 4 exam. Similarly,
well-documented state of treatment positive and compliant patients with affective
disorders are sufficient.
The same applies to the large field of conditions affecting sleep: Severe condi-
tions immediately prompt the action of specialists and might lead to immediate
revocation of a driver’s license, be it permanent or until successful treatment is
documented according to guidelines. With respect to sleep conditions, it is rather





MWT latency (average) ≥ 34 min 20–33 min < 20 min
MWT latency (single) < 20 min
single sleep fragments (<5 s) normal normal
Multiple sleep fragments (<5 s) X (repetition)
Longer sleep fragments (>5 s) X (repetition)







MWT latency (average) ≥
34 min
< 34 min
Any sleep fragements X
(6 month)
Table 3.
Evaluation of the fitness to drive based on MWT-sleep latencies and other parameters as measure in an MWT
according to current guidelines [10].
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the unclear cases, post hoc assessments of accidents and substance/medication-
related issues – mostly involving the danger of EDS – that are present in traffic
medicine.
4.1 Conditions leading to EDS
It is evident from the preceding chapters, that the symptom of a measurable
daytime-sleepiness (EDS) stemming from either behavioral aspects or medical con-
ditions is most relevant to traffic medicine in the assessment of the fitness to drive.
In the following section, we provide a brief overview over the prevalence and the
different medical conditions associated with EDS.
For lack of a general public health definition of EDS accessible to large-scale
public health studies, the determination of the prevalence of EDS has proven to be
difficult. With estimated prevalence ranging between 3.2 to 32.5% as reported in
[37], valuable information for orientation is provided by yearly polls of the U.S.
National Sleep Foundation [38]. The 2008 poll reports, that around 30% of partic-
ipants concede to sleepy/drowsy driving at least once per month during the last
year, mostly to and from work ([39], p. 32). While this number is highly subjective,
ESS-data provide a slightly less subjective or more systematic orientation about self-
assessed sleepiness: accordingly, 18% of the participants scored 10 or more points
qualifying them as excessively sleepy with increased likelihood of medical condi-
tions [40]. A more stringent report [37] analyzed data from 5,962 face-to face
interviews within the National Comorbidity Survey Replication (NCS-R), resulting
in a prevalence of EDS of 23%. This study identified individuals with significant
impairment/distress due to “excessive sleepiness (ExS.)” based on reported sleepi-
ness in conjunction with an irrepressible need for sleep, difficulty waking up and/or
prolonged nighttime sleep that was unrefreshing [37].
In Table 4, we summarized and categorized possible origins for EDS by (a)
Sleep deprivation, i.e. too little sleep in general, be it behavioral or situational, (b)
Reasons for fragmented sleep be it for environmental or medical reasons, (c) Pri-
mary CNS related hypersomnia, including narcolepsy, (d) “True” neurological
conditions that might be associated directly or indirectly with altered sleep e.)
Psychiatric conditions often accompanied directly or indirectly with altered sleep
and, lastly, (recreational or illicit) substances/stimulants or medications that typi-
cally induce EDS and/or sleepiness. Due to its focus on the outcome sleepiness,
rather the table might seem somewhat arbitrary. However, this categorization
should not be confused with a classification of sleeping disorders per se as in, for
example [42], or the new ICSD-3 [30–32].
We therefore added coloring, indicating items in different categories that are
accessible to similar treatment/changes. Accordingly, basically all reasons for sleep
deprivation, sleep fragmentation by environmental reasons and most substance
induced reasons for sleepiness/EDS are accessible to behavioral/situational change
(light blue) Obstructive sleep apnea syndrome and Obesity Hypoventilation Syn-
drome are accessible to device assisted treatment (CPAP, APAP, servo ventilation,
gray).
While narcolepsy and epilepsy are often well manageable with relatively mild
medication (light red), many primary CNS hypersomnia and neurological condi-
tions, including RLS and PLMD are less accessible to treatment or require more
complex care management (gray-blue). Similarly, the most other organic condi-
tions require complex medication including symptomatic pain relief (yellow, see
opiates). Lastly, care and medication psychiatric conditions requires specialized
attention with respect to EDS and sleepiness, in particular in the context of the
fitness to drive (light green).
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As the occurrence of EDS is trivial or at least likely in cases of hypersomnia or
neurological disorders, respectively, specialist case management addresses this
danger usually in a very efficient manner. Consequently, traffic medicine rarely
receives unclear cases stemming from these conditions. Rather, traffic medicine is
usually only required to assess and document the requirement for regular reports of
lower level experts - in most cases the patient’s physician - to the authorities.
EDS can be caused, on the one hand, by short- or long-term (miss-) behavior
(i.e. “partying) or working conditions such as night or shift work [43]. On the other
hand, it can stem from medical conditions, such as narcolepsy [44], hypersomnia
[45], OSAS [46], RLS [47], or medication, such as anti-histaminica or antidepres-
sants [48, 49]. In the clinical setting, two of the most commonly encountered causes
leading to EDS are obstructive sleep apnea, restless leg syndrome and periodic limb
movement disorder [41]. Other reports count non-apnea sleep disorders higher in
risk, but for all injuries, not limited to driving [50]. At the same time, several
reports [51] indicate, that also sleep medication- or sleep medication-withdrawal-
induced psychomotor impairments/disorders, such as REM-sleep behavior disor-
der, RBD, might lead to parasomnias and, in consequence, EDS [42].
While our own records indicate only 114 out of 256,387 entries indicate a clear
sleep accident (search term “Einschlafunfall”) of various origins, we do find 750
and 1,904 entries for the term OSAS or sleep apnea (search term “Schlafapnoe”),
respectively 170 entries are retrieved for sleeping problems (search term
“Schlafstörung”), 125 for restless-leg syndrome and 111 entries for narcolepsy. Only
17 entries can be retrieved for hypersomnia.
The potentially multifactorial origin of EDS shows exemplarily the importance
of a full anamnesis and complete medical examination in traffic medicine. We
illustrate this by way of a case study.
4.2 Case study 1: uncovering a case of OSAS-induced EDS
One morning in March, around 7 am, a 62-year-old man drove at moderate
speed on a straight street to work. According to eyewitnesses, the driver’s car
moved more and more towards the lane of the oncoming traffic. After two small
grazing collisions, a frontal collision at moderate speed ended the drive. The driver
reported a “blackout” and declared no recollection of the initial grazing collisions or
ignition of the airbags. He reported to be “fully back” immediately after the frontal
crash. He stepped out of the car unharmed, called the police helped the other driver
and secured the site. Subsequently, a “wave-like” uneasiness with low pulse
(40 bps) set in, which lasted for around 3 hours. As neither he nor the police could
clearly identify a sleeping incident and he claimed a blackout, the police revoked his
driving license based on a first-time TLoC until final assessment in traffic medicine.
He was hospitalized for 3 days for both security and further check-ups.
For the traffic medical exam, which took place 5 months later in August, the
patient presented himself in good physical and mental conditions. He reported to be
in good health, to have been active, to drink usual amounts of alcohol and to be fully
drug-naïve. He reported plans to retire abroad the following year after 40 years of
successful work. He is unable to explain the blackout, as he has driven this route to
work about “100,000 times”.
Extensive medical exams included cardiological, neurological and neuro-
angiological reports, including overnight EEG. While epileptiform spike-patters
were observed when falling asleep, these were considered norm variants and not to
causative for a blackout. However, strong snoring and a medium-grade OSAS was
reported with an AHI of 33 although this was restricted to unusual sleeping posi-
tions (back). The patient was surprised about this finding and reported to notice no
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negative physical effects of this condition. Only, his wife moved out of the bed-
room due to the snoring. As there was no evidence excluding a TLoC and indica-
tion for an OSAS – although without clear signs of EDS – the permission to drive
was not re-granted. This assessment could be reconsidered, provided the patient
had proof for no further TLoC-like events within a year and could provide a
repeated polysomnographic examination for confirmation of the moderate state of
his OSAS.
The patient presented himself 13 months later (September) with the following
records: A second PSG (performed December the previous year) reported a severe
OSAS with AHI of 77, ESS 3/27 with subjectively normal sleep. At this point, a MWT
was performed, but was considered non-evidentiary, such that there is no result
reported. APAP treatment was initiated in January. An MWT performed in May
confirmed inconspicuous (4 x > 40 min) with very good patient compliance. The
snoring had subsided and the wife had moved back into the shared bedroom.
Despite clear signs for a sleep accident, the initial round of examinations only
revealed unclear results, except indications for an un-diagnosed sleep condition
(OSAS) from the wife’s reports and a first nighttime-EEG. Here the patient’s com-
pliance is exemplary. Based on this and no further indication of a TLoC-like event,
the assessment supported re-granting the license on the condition of yearly follow-
up reports. Most likely due to his retirement and relocation abroad the patient was
lost to follow-up in our files.
In conclusion, it is in the interest of the individual driver’s safety and traffic
safety in general to obtain a full anamnesis and medical examination in traffic
medicine. While traffic medicine is primarily neither a diagnostic nor therapeutic
instance, traffic medicine’s unique perspective, mandate and its concomitant in-
depth assessment of the medical fitness to drive allows detecting previously
unreported cases of EDS.
However, an EDS based on medical condition might be obscured or – vice versa -
incorrectly assumed, when other conditions require medication that potentially
leads to sleepiness. This will be highlighted in the following chapter that introduces
the dimension of depression, age and behavior in the context of inappropriate use of
medication, such as antidepressants and sleeping pills.
5. Substance (ab/mis)use and the fitness to drive
As outlined in Section 2, active participation in traffic requires adequate physical
and psychological performance and reserve capacities. With any medication or
substance taken, one’s overall performance might improve or worsen. While many
substances might reduce performance in a noticeable, but manageable fashion,
some might induce (daytime) sleepiness. This is particularly true for most psycho-
active substances, either in its wanted or unwanted effects (such as lag, hangover,
rebound, side effects, and paradox reactions).
Somewhat trivial but not always known, this is clearly true for sleeping pills,
(hypnotics/ hypnosedativa), but also for medication in psychiatric disorders (anti-
depressants, antipsychotics), allergies (antihistaminic) and, partially, degenerative
disorders (e.g. Parkinson) [52]. Therefore, traffic medicine needs to know how to
evaluate the fitness and the ability to drive under the influence of such medication.
As described in the first paragraphs of this section, this is particularly important if
such medication is combined, as often – but not exclusively - the case of elderly
drivers.
We then provide a brief sketch of historic improvements and persisting prob-
lems of the above classes of drugs, with a focus on potential issues for safe driving
14
Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy
related to sleep, leading general recommendations for experts based on a classifica-
tion by the International Council on Alcohol, Drugs and Traffic Safety, ICADTS.
Subsequently we evaluate potential issues of excessive self-medication (melatonin,
doxylamine) and the (ab)use of (illicit) drugs such as cannabis, barbiturates and
opioids. By way of a case example, we highlight the value of hair sampling for
controlling long-term substance (ab)use.
5.1 The triangle depression, sleep, and age
According to a recent report of the Swiss health observatory (Obsan) from 2016
[53], a substantial fraction of the Swiss population feels heavily (5%) or moderately
to heavily (13%) burdened with mental and psychological problems. Consequently,
18 out of 100 are likely to present mental disorders. Yearly prevalence varies by
year: most frequent are anxiety disorders (14%), affective disorders (7.8%),
somatoform disorders (4.9%) and alcohol-related disorders (3.4%). Almost 90% of
all affective disorders are depressions (6.9% of total). Around 5% of the Swiss
population take either hypnotics on a daily basis. About 40% of the population with
mental problems take antidepressants. In both groups, women are more prevalent,
and the incidence increases strongly with age [54]. Importantly, there are indica-
tions that there is a gender difference in driving performance when using hypnotic
medication [55].
While antidepressants alone might have strong effects on driving performance
via sleep disturbance [14], initial symptom of above mentioned mental disorders
(or of the prolonged stress periods leading to mental disorders), is heavily disturbed
sleep, directly linking an increased use and prescription of psychopharmaca to that
of hypnotic medication, i.e. sleeping pills, the latter often being benzodiazepines or
Z-Drugs [53].
These figures have increased in the last decades [56] and steep increases in these
figures are to be expected as a consequence of the severe social restriction due to the
corona pandemic. Here, sleep patterns that are altered due to the lack of social
control (school, home-office, retirement and lack of social contacts) might them-
selves contribute to the etiology of psychiatric disorders and stress-syndromes, in
particular in children and adolescents. Conversely, the demographic increase of
elderly drivers with increasing rates of comorbidities and concomitant multi-
medication might potentiate the relevance of drug interactions in traffic on the
other side of the age spectrum. However, even without age-related conditions or
depression, the elderly often report sleep issues, which are loosely remedied by
standard hypnotics, such as Z-Drugs and benzodiazepines, or self-medication by off
label use. [57]
Here, many patients naively presume that prescribed or OTC medication does
not pose a risk in traffic and do not even mention taking it in an assessment.
Similarly, the addictive potential of some of the medication and “doctor hopping” to
obtain a desired drug should not be underestimated, even in highly regulated
markets such as Switzerland. Such unmonitored self-medication might result in
adverse side effects and unexpected drug interactions.
5.2 General recommendation for prescribing doctors and classification of
medication
In any case, the above unknowns poses a series of problems for both prescribing
doctors and experts in traffic medicine. Whenever assessing the FTD or prescribing
new medication experts should answer the following set of questions:
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• Does a medication have positive and/or negative effects on physical and mental
performance and reserve capacity required for safe driving, and if yes, how
much? Is the result balanced?
In other words: Does the medications main effect sufficiently increase physical
and mental performance and reserve capacity required for safe driving? Do the
medication’s undesired effects lower the physical and mental performance and
reserve capacity required for safe driving?
• How long the medication should be prescribed?
• Are there long-term consequences of the treatment (Parkinson, L-Dopa, wear-
off effects), indicating negative progression and thus narrower control
intervals of the FTD?
• Is there addictive potential associated with the drug?
• Is the medication taken correctly? Are compliance and adherence given?
• Do any indications exist, that call for checking adherence/compliance by
blood-level testing or similar?
While information relating medication to accident risks or odds ratios exists
[57], it is limited and painstaking to collect. However, both on the acute level (i.e.
the ability to drive) and the long term (the fitness to drive) it is widely undisputed
that psychotropic drugs do affect the capabilities for safe driving: very simply
speaking, hypnotic, sedatives and antidepressants are prescribed to calm down, to
lower activity level and/or to fall asleep. It seems, on the one hand, thus, rather
trivial that these desired effects might have spill-over-effects of the ability to drive.
It is not trivial on the other hand, to collect and categorize the existence and,
subsequently, the extent of such effects on safe driving. Thankfully, the large-scale
EU-Project DRUID (Driving Under the Influence of Drugs) that included partici-
pation of the ICADTS presented an aggregated list of medications affecting safe
driving [58, 59] and published according prescription guidelines [57].
Listed drugs were classified as follows:
I.Presumed to be safe or unlikely to produce an effect
II.Likely to produce minor or moderate adverse effects
III.Likely to produce severe effects or presumed to be potentially dangerous
All antidepressants/-psychotics and hypnotics are listed in category II or III. The
most relevant drugs are listed in Table 5, possibly a helpful tool for both physicians
and experts.
Wherever know, detailed information is provided as to how long not to drive
after changes in the respective medication. As a general rule of thumb from the
perspective of traffic medicine, patients should abstain from driving for a period of
about 14 days after treatment start, change or end of a treatment regime.
With every change in medication, the effects of prescribed drugs as well as the
duration of effects on driving should be explained in detail. The recommendation to
abstain from driving and the warning information should be registered in the
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Active ingredient Classification Active
ingredient
Classification
ANTIPSYCHOTICS BENZODIAZEPINES + Z-DRUGS
Levomepromazine III Diazepam III
Fluphenazine II Chlordiazepoxide III




Haloperidol II Lorazepam III
Melperone II Bromazepam III
Pipamperone II Alprazolam III
Benperidol II Flurazepam III
Flupentixol II Nitrazepam III
Zuclopentixol II Flunitrazepam III
Clozapine II Triazolam III
Olanzapine II Lormetazepam III 1 mg (capsule): >10 hours post dosing little
or no impairment (Category I)
Quetiapine II Temazepam III 10 mg: >10 hours post dosing little or no
impairment (Category I)
Sulpiride II Midazolam III
Amisulpride II Zopiclon III
Lithium II Zolpidem II 10 mg: >10 hours post dosing little or no
impairment (Category I)




Desipramine II Paroxetine I
Imipramine II Sertraline I
Clomipramine II Fluvoxamine I
Trimipramine III Escitalopram I
Amitriptyline III Moclobemide I
Nortriptyline II Mianserin III
Doxepin I II Trazodone III
Melitracen II Mirtazapine III






Classification of hypnotics, anti-depressants and -psychotics, stimulants with respect to effects on driving
according to the DRUID study [58] in collaboration with ICADTS [60]. Excerpt from [59].
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patient’s records. After the initial treatment phase, patients should be controlled. If
there are clinical sings of, for example generally lowered response time, reduced
vigilance, reduced speed of perception processing or motoric effects, the patient
should not be allowed to drive as these severely affect the reserve capacity for safe
driving substantially.
In particular, drugs carrying an addictive potential should not be prescribed for
long terms and their appropriate (therapeutic) dosage and use should be confirmed
by blood-level testing.
5.3 Disappointed & false expectations: sleep medication and its effect on
driving in a historical perspective
Disturbances of sleep have always troubled humanity [61]. Sleep medicine as a
subject field in medicine has only evolved rather late (c. since the mid 1970s) but
fulminant [62]. This especially after linking mayor breakthroughs in measurement
technologies, findings and concepts such as the electroencephalogram, EEG [63],
detection of sleep-stages [64] including rapid eye movement sleep, REM, [65], to
the regulation and control of circadian rhythms and chronobiology [26, 66, 67].
Before bromides solutions emerged in the 1800s, it was mostly alcohol and drugs
such as opium and cannabis that served to induce or facilitate falling asleep. The
first effective synthetic hypnotic was chloral hydrate in 1869, followed by paralde-
hyde around 1880 and the introduction of the first of a long series of barbiturates
(phenobarbital, 1912) after initial synthesis of the founding compound barbital in
1903.
While the above substances were introduced well before the public had wide-
spread access to such medication or, for that matter, driving, their addictive poten-
tial and recreational use remain a problem in traffic medicine today.
Between the first and second world war, the extensive, indiscriminate and
uncontrolled use of barbiturates (and for that matter other drugs [68]) such as,
phenobarbital, secobarbital, amobarbital and pentobarbital in the general popula-
tion coincides with an increase of cars and traffic density.
This increase in cars and traffic density accelerated drastically with the begin-
ning of the second half of the 20th century, motivating a further evolution of traffic
medicine, more and more including the control of addictive substances. This devel-
opment parallels a boost in the development in sleep medicine (see above) but also
coincides with the development and increasingly widespread use of the next gener-
ation of hypnotics, the benzodiazepines, which today are still one of the most
widely prescribed group of medication.
The lower number of unfavorable side effects of benzodiazepines as compared
to barbiturates led to brad use as a household hypnotic, severely underestimating
the development of tolerances, addiction and side effects. As above mentioned for
early sleep remedies, the (by-)use of benzodiazepines in recreational settings keeps
this class of hypnotic well in the focus of traffic medicine even nowadays [14] .
Much like in other, earlier cases (radium, heroin, pervitin [68]) the repeated
promise of “side-effect-free” medicine proved to be naïve and incorrect again. In
particular, benzodiazepines are associated with a rather large number of psycho-
motor disorders indirectly affecting sleep in a negative way [51].
Initially, this seemed to be different with a new group of hypnotics, arriving in
the late 1980ies: the non-benzodiazepines, often called Z-Drugs [69], promised to
be specific and highly effective hypnotics. However, identical pharmacodynamics
as compared to benzodiazepines indicate paths to similar side effects. These are,
however, sometimes slightly less pronounced or just different: Z-Drugs seem to
have lower tendency for physical dependence and addiction, but are known to
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produce amnesia and, rarely, hallucinations. Counterintuitively, some of the Z-
Drugs double the risk of developing depression and some long-terms studies found
a marked increase in suicide risk [70]. Zolpidem itself is associated with rebound
insomnia, possibly resulting in subsequently aggravated EDS. In Contrast to
zolpidem and zopiclone, zalepon is not associated with an increased risk of motor
vehicle accidents [71]. However, effects of Z-Drugs on human performance includ-
ing some rather bizarre behavioral effects heavily affecting sleep have been sum-
marized [69].
Nowadays, swift and thorough testing the effects of novel - and supposedly
again more specific - hypnotics on driving performance [72] prevents major sur-
prises in novel sleep medication with respect to effects on driving performance.
This includes orexin system blockers, such as Suvorexant [73] and Lemborexant
[74], or melatonin agonists [66, 67], such as Ramelteon [71, 75].
This also applies to reevaluation of older information [76, 77] concerning driving
performance after the “rediscovery” of some tricyclical antidepressants, such as
doxepin (Silenor) [78] which effectively trigger sleep onset in an antihistamine-like
fashion, i.e. by selectively blocking H1-receptors.
As mentioned above for the older generations of dedicated hypnotics, older
generations of other medication have been - and are still - used to facilitate or
induce sleep based on their side effects. However, the negative consequences on
driving performance might however be even more pronounced than in modern
hypnotics. Depending on a countries medical system, this self-medication is more
or less uncontrolled. Here in particular, ab- or miss-use of over the counter drugs
might be risky in traffic. Additionally, some of these substances are likely to be part
of an addictive behavior. Some substances have even become literally “traditional”
to the degree of “folklore”. To mention here directly are, among others, first-
generation antihistamines such as doxylamine (e.g. Sanalepsi, Unisom), diphenhy-
dramine (e.g. Benadryl, Nytol), but also partially available antitussives such as
codeine (e.g. Mucatussin) but also the inappropriate use of melatonin pills with
questionable results on sleep, but potentially sever impacts on driving performance
[79–81].
With this plethora of information to deal with, it is to be expected that
unintended and uniformed misuse of individual or combined medication might lead
to sleepiness on the wheel, potentially resulting in severe accidents. Similar to
unknown medical conditions, it is again traffic medicine’s mandate to “elucidate”
the exact or at least most likely cause of such accidents. Very often a thorough
anamnesis and sighting of all available records is insufficient to give conclusive
results. It is then, that modern tools of forensic pharmacology and toxicology come
into play, much like in the case of drug checking [82]. Unless take at – or in timely
context of – the incident urine and blood sampling suffer from the low diagnostic
window and are mostly useless. In contrast, high-resolution hair-sampling might
provide valuable information over considerable time-spans [83], which also allows
to confirm or falsify previous information form anamnesis or testimonials.
5.4 Case study 2: uncovering a medication induced sleep accident
One morning in May, a fifty-year-old woman cased an accident on the highway
in commuter traffic. She reported to have nodded off, causing the accident in
consequence. She also stated to have taken the sleeping pill Zolpidem and the anti-
depressant Trazodone the evening before and an additional antidepressant (Sertra-
line).
The toxicological examination of blood revealed in fact Zolpidem and Trazodone
in therapeutic concentrations and Sertraline in sub-therapeutic concentrations.
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Accordingly, the toxicological assessment postulated an improper use of the hyp-
notic, as Zolpidem was detected at such high concentrations in the morning, despite
its short half-life. According the ability to drive (ATD) at the time of the accident
was impaired due to improper medication. Accordingly, the road safety authorities
ordered for a full traffic medical assessment including a traffic medical examination
at level 4.
Here, the women reported to have started taking Trazodone two years prior to
the accident as she had developed sleeping problems due top psychosocial prob-
lems. Trazodone and Sertraline had been prescribed by her psychiatrist. Addition-
ally, her practitioner had prescribed Zolpidem from time to time. She reported to
have taken Zolpidem only rarely, as she had gotten to know of its addictive poten-
tial. At the time of the examination, she had ceased to take Zolpidem already for a
period. She explained the situation and the resulting accident by accidentally
mixing up Zolpidem and Sertraline.
A routine laboratory set for drugs was ordered, In addition, a segmented hair
analysis was performed to confirm discontinuation of Zolpidem use.
Status: The patient presented herself in good general condition,
cardiopulmonally compensated, no neurological defects, and psych status after
MADP inconspicuous/nondescript.
Therapy at exam: Trazodone, Sertraline.
Routine Laboratory:
Urine: Tetrahydrocannabinol (THC), Cocaine, Methadone, Benzodiazepines,
Amphetamine, Methamphetamine, Opiates, Barbiturates, Ecstasy, Buprenorphine,
Zolpidem, Tramadol, Fentanyl, Ketamine, MDA, Methaqualone, Methylphenidate,
Oxycodone, Phencyclidine, Propoxyphene, Spice/K2, Zaleplon: negative, Trazo-
done, tricyclic anti-depressants: positive.
Hair Analysis Results: (Benzodiazepins und Z-Drugs):
1.Segment: ca. 3 cm (proximal, younger, estimated July–September): Zolpidem
49 pg./mg
2.Segment: ca. 2 cm (distal, older, estimated April–June): Zolpidem 120 pg./mg
In all, anamnestic and laboratory information was sufficient to conclude, that
there was no continued medication ab- or misused. The information supported the
patient’s explanation of a singular medication mistake. The patient was compliant
and adherent. The MMR’s are given and the fitness to drive could be affirmed.
6. Concluding summary
By way of data form so-called “developed” countries we illustrate a striking
prevalence of and, subsequently, an imminent threat for traffic safety by sleep-
related disorders. In line with the ambition to minimize fatalities, Switzerland
approaches mitigating such (and other medical) threats by defining medical mini-
mum requirements for a driving license. Regular or incidence-related control of
these requirements in a highly structured process in traffic medicine reflects one
possible strategy that is logically consistent with highly regulated health care,
administration and society in general. However, the threat form sleepy driving is
universal and fundamentally independent of “development” or location. Thus,
consolidated expert advice depends largely on facilitated exchange of unequivocal
information, potentially even at the danger of oversimplification. In this line, we
argue for a more consistent use of the term “sleepiness” and its signs. We
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furthermore suggest a more consistent use of standardized measurements (MWT)
to detect excessive (or existent) daytime sleepiness (EDS) as the most relevant
consequence of sleep conditions met most often in traffic medicine (OSAS, narco-
lepsy, substance induced EDS). It is often not strikingly bizarre sleep disorders but
rather unidentified ones that present the highest risks for traffic. Thus, we inform
about simple but clear signs of sleepiness. This is to sensitize both practitioners and
experts. These should have an open eye a.) for the interplay between seemingly
unrelated conditions potentially leading to EDS affecting the fitness to drive and b.)
for the relevance of uncontrolled, uninformed and unintentional substance ab- and
misuse affecting the ability to drive. In particular, the latter aspect depends not only
on a particular legal and administrative framework’s setup, but also on the general
or individual attitude in society.
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